Skip to main content
SpringerLink
Log in

Optimising the diagnostic value of Anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn’s disease

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background/Aims

Anti-Saccharomyces cerevisiae-antibodies (ASCA) are used to discriminate Crohn’s disease (CD) from ulcerative colitis (UC). ASCA tests are not standardised and different methods for ASCA detection exist. This study was undertaken to compare ASCA tests and to clarify their diagnostic value.

Patients/Methods

One hundred and two sera from CD patients, 53 from UC patients, and 50 sera from normal controls were examined for ASCA IgA and ASCA IgG using four different ELISA (Aesku.lab, Inova, Euroimmun, and Medipan) and indirect immunofluorescence (Euroimmun). Sensitivity, specificity, and positive and negative predictive values (PPV and NPV) for CD in this population were determined. Agreement between tests was expressed by kappa statistics.

Results/Findings

The presence of either ASCA IgA or ASCA IgG had a PPV between 77 and 88%. Only the combined presence of ASCA IgA and ASCA IgG had a specificity which was constantly above 90%. Sensitivity, specificity, PPV, and NPV were then: Inova: 53, 97, 95, and 68%; Euroimmun ELISA: 46, 97, 94, and 66%; Aesku.lab: 50, 97, 94, and 66%; Medipan: 30, 98, 94, and 59%; indirect immunofluorescence: 51, 97, 94, and 66%. Agreement between ELISA test results of the Aesku.lab, Euroimmun, Medipan IgA and Inova systems was good (kappa: 0.63–0.79); between the Medipan IgG ELISA or indirect immunofluorescence and the others, it was lower (kappa: 0.33–0.6). If both ASCA IgA and ASCA IgG were detected by indirect immunofluorescence as well as ELISA, specificity for CD increased to >99% at a sensitivity of 23–38%.

Interpretation/Conclusions

The combined detection of ASCA IgA and ASCA IgG by indirect immunofluorescence as well as ELISA may optimise the discrimination of CD from UC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a, b.

Similar content being viewed by others

References

  1. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D (1998) Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42:788–791

    CAS  PubMed  Google Scholar 

  2. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P (2001) Diagnostic value of Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 96:730–734

    Article  CAS  PubMed  Google Scholar 

  3. Sandborn WJ, Loftus EV, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR (2001) Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 7:192–201

    Article  CAS  PubMed  Google Scholar 

  4. Koutroubakis IE, Petinaki E, Mouzas IA, Vlachonikolis IG, Anagnostopoulou E, Castanas E, Maniatis AN, Kouroumalis EA (2001) Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 96:449–454

    Article  CAS  PubMed  Google Scholar 

  5. Moore MM, Fabricatorian D, Selby WS (2002) Assessment and relevance of enzyme-linked immunosorbent assay for antibodies to Saccharomyces cerevisiae in Australian patients with inflammatory bowel disease. Intern Med J 32:349–352

    Article  CAS  PubMed  Google Scholar 

  6. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel JF (2002) The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122:1242–1247

    PubMed  Google Scholar 

  7. Folwaczny C, Noehl N, Endres SP, Loeschke K, Fricke H (1998) Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scand J Gastroenterol 33:523–528

    Article  CAS  PubMed  Google Scholar 

  8. Seibold F, Weber P, Klein R, Berg PA, Wiedmann KH (1992) Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 33:657–662

    CAS  PubMed  Google Scholar 

  9. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG (1998) Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 115:822–829

    CAS  PubMed  Google Scholar 

  10. Kull K, Salupere R, Uibo R, Ots M, Salupere V (1998) Antineutrophil cytoplasmic antibodies in Estonian patients with inflammatory bowel disease. Prevalence and diagnostic role. Hepatogastroenterology 45:2132–2137

    CAS  PubMed  Google Scholar 

  11. Seibold F, Weber P, Schöning A, Mörk H, Goppel S, Scheurlen M (1996) Neutrophil antibodies (pANCA) in chronic liver disease and inflammatory bowel disease: do they react with different antigens? Eur J Gastroenterol Hepatol 8:1095–1100

    CAS  PubMed  Google Scholar 

  12. Vasiliauskas EA, Kam LY, Karp LC, Gaienne J, Yang H, Targan SR (2000) Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 47:487–496

    Article  CAS  PubMed  Google Scholar 

  13. Klebl FH, Bataille F, Bertea CR, Herfarth H, Hofstädter F, Schölmerich J, Rogler G (2003) Association of Vienna classification subtypes of Crohn’s disease with pANCA and ASCA. Inflamm Bowel Dis 9:302–307

    Article  PubMed  Google Scholar 

  14. Bernstein CN, Orr K, Blanchard JF, Sargent M, Workman D (2001) Development of an assay for antibodies to Saccharomyces cerevisiae: easy, cheap and specific for Crohn’s disease. Can J Gastroenterol 15:499–504

    CAS  PubMed  Google Scholar 

  15. Seibold F, Stich O, Hufnagl R, Kamil S, Scheurlen M (2001) Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol 36:196–201

    Article  CAS  PubMed  Google Scholar 

  16. Glas J, Török HP, Vilsmaier F, Herbinger KH, Hoelscher M, Folwaczny C (2002) Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: potential clinical value. Digestion 66:173–177

    Article  CAS  PubMed  Google Scholar 

  17. Linskens RK, Mallant-Hent RC, Groothuismink ZMA, Bakker-Jonges LE, van de Merwe JP, Hooijkaas H, von Blomberg BME, Meuwissen SGM (2002) Evaluation of serological markers to differentiate between ulcerative colitis and Crohn’s disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol 14:1013–1018

    Article  CAS  PubMed  Google Scholar 

  18. Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P (2001) Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 120:827–833

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank Mrs. Claudia Wögerbauer and Mrs. Dita Fritsch for their excellent technical assistance.

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, University of Regensburg, 93042, Regensburg, Germany

    Frank H. Klebl, Hans Herfarth, Jürgen Schölmerich & Gerhard Rogler

  2. Institute of Pathology, University of Regensburg, Regensburg, Germany

    Frauke Bataille & Ferdinand Hofstädter

Authors
  1. Frank H. Klebl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frauke Bataille
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ferdinand Hofstädter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans Herfarth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jürgen Schölmerich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gerhard Rogler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank H. Klebl.

Additional information

Supported by the Bundesminsterium für Bildung und Forschung (BMBF) Competence network “Inflammatory Bowel Disease”

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klebl, F.H., Bataille, F., Hofstädter, F. et al. Optimising the diagnostic value of Anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn’s disease. Int J Colorectal Dis 19, 319–324 (2004). https://doi.org/10.1007/s00384-003-0557-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-003-0557-1

Keywords

Search

Navigation